Ruxolitinib for the Treatment of Essential Thrombocythemia

Deregulated Janus Kinase 2 (JAK2) activation is central to the pathogenesis of most myeloproliferative neoplasms (MPNs), of which essential thrombocythemia (ET) is the most common entity. Patients with ET are risk-stratified according to their risk of thrombo-hemorrhagic complications. High-risk pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunawan, Arief, Harrington, Patrick, Garcia-Curto, Natalia, McLornan, Donal, Radia, Deepti, Harrison, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746005/
https://www.ncbi.nlm.nih.gov/pubmed/31723782
http://dx.doi.org/10.1097/HS9.0000000000000056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746005/
https://www.ncbi.nlm.nih.gov/pubmed/31723782
http://dx.doi.org/10.1097/HS9.0000000000000056

Ejemplares similares